CRI's new website that seeks to engage, educate, and empower patients and their loved ones to learn more about cancer immunotherapy as a treatment option across numerous tumor types.
Cancer patients, donors, scientists, and other supporters all stand behind the Cancer Research Institute. Read their stories and learn about what motivates each of us to keep fighting against cancer.
By running in a marathon or hosting a bake sale, you can make a real difference for our scientists in the fight against cancer and allow them to bring newer immunotherapies to more patients.
We gratefully accept donations made in memory or in honor of a loved one. Your gift will be acknowledged to whomever you specify.
Numerous challenges can slow progress in finding new immune-based cancer treatments. We're solving some of the biggest challenges, accelerating promising new immunotherapies for patients.
Curious about the latest developments in cancer immunotherapy research? Listen in as leading scientists discuss immune-based treatments across numerous cancer types in our free "Breakthroughs in Cancer Immunotherapy" webinar series.
When the Cancer Research Institute was founded in 1953, we knew then that immune-based treatments would transform cancer medicine. In more than six decades since, we've made numerous groundbreaking discoveries that have given more patients new hope today.
Welcome to the Cancer Research Institute blog. Here we share the latest updates on the field of cancer immunotherapy from CRI, including scientific breakthroughs, news stories, and program announcements. We invite your comments and encourage you to share these stories with your friends.
You can receive notifications of new posts by subscribing to our blog. Just click the RSS icon in the upper right corner.
September 19, 2015
CRI scientists review the state of cancer immunotherapy in the latest issue of Science magazine.
cancer immunotherapy, cancer research, in the news
cancer immunotherapy, cancer research, Coley's toxins, history
cancer immunotherapy, in the news
What’s ahead beyond CTLA-4 and PD-1?
cancer immunotherapy, checkpoint-inhibitor, combination therapy
Cancer immunotherapies can have some mind-boggling names. But there’s a reason for it all.
anti-PD-1, cancer immunotherapy, checkpoint-inhibitor, FDA approval, melanoma
annual report, cancer immunotherapy
bispecific antibodies, cancer immunotherapy, FDA approval, leukemia
cancer immunotherapy, in the news, patients, scientific leadership, survival, TheAnswerToCancer.org
cancer immunotherapy, cancer research, charity, givingtuesday